Section : Research Paper
ISSN 2063-5346

Proteasomes A Promising Drug Delivery-A Review

Preethi. N[1], Saraswathi T S*, Damodharan N[1]

*, 1 Department of Pharmaceutics, SRM College of Pharmacy,
SRM Institute of Science and Technology, Kattankulathur, Tamilnadu, India -603203.

*Corresponding author: saraswas1@srmist.edu.in

Abstract
A sophisticated big protein complex is called a proteasome. It is in charge of intracellular protein breakdown. Energy for metabolism is needed. A cellular complex called proteasome inhibitors degrades ubiquitinated proteins by attaching the lysine residue's side chain's amino group. this has become a potent therapy option for multiple myeloma (MM). The first-ever proteasome inhibitor is called bortezomib (PI). Carfilzomib is a PI of the second generation. These PIs have been used in a number of regimens along with other substances such as alkylators, immunomodulatory medicines, and monoclonal antibodies. This study provides an overview of the proteasome, its structure, proteasome inhibitors, biological effects, the outcomes of clinical studies looking at combinations of therapeutic medicines based on PIs, and potential future developments in the Myeloma treatment.

Introduction

The purpose of proteasomes is to hydrolyse client proteins in a selected, effective manner. It is well-recognized to work with ubiquitin. A signal for controlled proteolysis in eukaryotic cells is formed when it polymerizes. Many target proteins receive a destruction signal when ubiquitin polymerizes with the proteasome. Due to their enormous diversity, E3 (ubiquitin-ligating enzyme) proteins can recognize a protein substrate for ubiquitylation. Patients with multiple myeloma are living longer thanks to proteasome inhibitors (PIs). It serves as the foundation for all stages of contemporary MM therapy. Significant amounts of secretory protein are produced by MM cells. So, a great deal depends on how well the proteasomes work. Proteasome suppression in MM throws off the balance between making new proteins and getting rid of old, damaged ones. It causes apoptosis, excessive unfolded protein response activation, and proteotoxic stress. Hence, all PIs for MM therapy that are clinically accessible are made to target the 5subunit of the constitutive proteasome and immunoproteasome. MM cells are thus made more susceptible to therapy with bortezomib and carfilzomib by co-inhibition of 1 or 2 subunits. The myeloma cells will accumulate and be killed by the PIs.Bortezomib, carfilzomib, and ixazomib are the three PIs currently being used to treat multiple myeloma (MM). As of late, carfilzomibThe 5-subunit of the constitutive proteasome binds irreversibly to this protein and inhibits covalent hydrolysis and has become a current treatment option for patients with relapsed and/or refractory multiple myeloma (MM). The biological effects of these PI-combination therapy medicines are summarised, along with their pivotal clinical studies, in this review, which also covers the prospects for treating MM in the future.

Section : Research Paper
ISSN 2063-5346

Structure of Proteasomes
20s and 30s proteasome

The proteasomes, which contain two sub complexes: one is a catalytic core particle (the 20s proteasome), and another is one or two terminal 19s regulatory particles with a molecular massofaround 700 kDa that function *as* a proteasomeactivatorto generate an enzymatically activatedproteasome[1]–[4].There is an attachment between the 19s and the 20s proteasome on both ends.The elongated 30S molecule may also contain symmetrically arranged 19S RPs in addition to the central portion of the complex[5]. A 19S RP might be attached to the 20S proteasome in order to form the 26S proteasome, which may explain the difference in size between the two structures[6], [7].



Fig 1 Eukaryotic 20S core proteasome from saccharomyces cerevisiae

This is the model of a eukaryotic 20S "core "proteasome (from saccharomyces cerevisiae) bound to two 19S regular caps. This is just a model showing the very basic shape of 19S that is divided into a "base"-ring containing six subunits binding the a-ring of the 20S "core" proteasome and a "lid" containing nine subunits, responsible for recognition, binding, and unfolding of polyubiquitinated substrates, feeding them into the 20S proteasome for terminal degradation.

Core particle or 20S proteasome

It is a well-organized protein complex with a molecular mass of around 750 kDa and a sedimentation coefficient of 20S. The 20S proteasome is visible under electron microscopy in a variety of eukaryotes, including yeast and humans, as a cylinder-like structure. Two outer rings and two inner rings, each made up of seven structurally comparable and subunits, are stacked axially to produce a packed particle. The rings together make up a α1-7β1-7β1-7α1-7 structure. The compound with C2 symmetry contains the proteasome subunits specifically.Client proteins are processed by the 20S proteasome into oligopeptides with lengths ranging from 3 to 15 amino acids. Oligo peptidases and/or amino-carboxyl peptidases

Section : Research Paper
ISSN 2063-5346

then hydrolyze the peptide products into amino acids.Whilst the binding of denatured proteins to the closed -αring appears to aid in the gate opening, the mechanisms governing these processes are poorly understood[8], [9]. It remains unclear presently whether the proteasome 20S is able to carry out in vivo proteolysis without assistance from further activators[10]. Although this procedure has been studied in vitro, it has not been tested *in-vivo* yet.

Regulatory particle or PA700

On one or both ends of the central 20S proteasomal core, the enzymatically dynamic proteasome is regularly encased by administrative proteins. The RP recognizes client proteins distinguished by polyubiquitin chains, breaks the bond and captures the protein moiety, unfurls the substratum proteins, opens the α-rings, and after that transports the unfurled substratum into the CP for apoptosis. A regulatory particle is build-up of approximately 20 subunits, including a regulatory particle of triple-ATPase subunits as well as a regulatory particle of non-ATPase subunits. The molecular weight of the proteins in each of these subgroups varies between 10 and 110 kDa[11], [12].

Proteasome activator-28 and hybrid proteasome

Another protein that activates the dormant 20S proteasome is PA28 or the 11S regular (REG)[13]. According to an electron microscopic analysis, PA28 interacts with at each end of the middle 20S CP to produce conical caps. Three structurally related components known asα, β andγ, and make up PA28 complexes; their main structures share around 50% of their similarities. The PA28γ seems to form homo polymeric complexes, whereas the PA28α and PA28βcombine into hetero oligomeric complexes with alternating and subunits[14]. According to an immunofluorescence investigation, PA28α and PA28β are both mostly found in the cytoplasm, whereas PA28γ is primarily found in the nucleus outside of the nucleolus[15]. Recombinant REGα (PA28α) underwent X-ray crystallographic investigation, which identified a heptameric complex[16].

Proteasome activator or Blm10

Although there are conflicting reports on the exact functions ofBlm10 is thoughtto regulate proteasome assembly or proteolytic activity[17], [18]. Yeast-purifiedproteasomeprecursors containing Ump1 containedBlm10.Under normal circumstances, Blm10-deficient cells developed seemingly normally, but Ump1 yield and β5 processing were sped up, suggesting a function in avoiding the premature development of 20S proteasomes[19]. Contrarily, Blm10 supports proteasome development, likely by balancinggrowing proteasomes 20S, as shown by the substantial reduction of proteasome activity. And β2 processing caused by the combination of Blm10 deletion and β7 C-terminal truncations[20]. The contradiction between Blm10's two contradictory roles is yet unresolved.By opening an axial into the proteolytic chamber, Blm10 adjusts to the end of the core particle cylinder where it is perfectly placed to initiate the certainly inhibited CP, according to studies utilising electron microscopy (EM)[17]. The nuclear protein PA200, on the other hand, which is also broadly expressed, encourages the proteasomal hydrolysis of peptides but not proteins[18]. Fascinatingly, removing PA200 caused a considerable drop in man fertility but not woman fertility, revealing a crucial essential role for PA200 during spermatogenesis. It is also noteworthy that PA200 killer blow mice are healthy have no evident advancingmalformations.

Section : Research Paper
ISSN 2063-5346

PI31

The previously reported inhibitor of 20S proteasomes, PI31, reveals that it is a critical factor in the regulation of proteasome activity[21].Blocksproteasomeactivation by both proteasome regulatory proteins, PA700 and PA28. PI31 is a proline protein, with 26% of the amino acids beingproline,especiallyinitscarboxy-terminal half,and the protein appears to have extensive secondary structure.The PI31 proline-rich domain inhibits proteasomes. Yet, Based on the observation that PI31 preferentially suppresses the maturation of immunoproteasome precursor complexes, it is also asserted that Proteasome production and proteasome-mediated antigen processing are initiated by PI31 within the cell[22].

Diversity of proteasome

Because of its essential roles in cells, thecomplex of proteasome has been substantially preserved throughout progression. Budding yeast possesses seven -α and -βtype subunits, which is compatible with the 20S proteasome's seven-subunit -α and -βring. Vertebrates, on the other hand, β have significantly more than seven type components. As a result, the system of proteasome in vertebrates has a high degree of variety among the subunits, which progressed during the development of accommodative immunity. In this area, I will discuss the proteasome's various purposes, with a focus on its immunological plays. Furthermore, several proteasome genes are found in flies and plants, however their biological roles remain unknown[23].

Proteasome assembly

How the intricate 20S and 26S proteasome structures are set up is still mostly unclear. For instance, it is not entirely clear how the numerous groups of different but structurally related subunits are positioned correctly in the 20S proteasome. Recent studies have focused on the development of eukaryotic 20S proteasomes, which are made up of 28 subunits, all of which has a specific location inside the 20S particle.

Proteasome interacting proteins

Auxiliary components that are physically or momentarily linked to the 26S have been found by recent proteomic investigations[24]–[26]. These components have both known and unidentified activities. Two groups can be made from it. Protein components connected to the ubiquitylation mechanism are found in the first group. The second subset of components controls proteasome activities through direct binding.

Proteasome inhibitors

These results suggest that more PI-resistant patients may benefit from high dose carfilzomib[27].Throughout the past ten years, the use of PIs has been the cornerstone of myeloma therapy[28], [29]. In the preclinical and clinical settings, a large number of PIs are being produced and assessed[30].The primary process for protein degradation of nucleus and cytoplasm of eukaryotic cells is the ubiquitin proteasome pathway (UPP)[31].Because of the build-up of unfolded and abnormally folded proteins that PIs produce, the ER is stressed, reactive oxygen types are produced, JNK and proteasome53 are activated, cyclin-dependent inhibitors are expressed[32]. And also pro-apoptotic proteins are expressed[33], [34]. According to a recent study, cytotoxicity and considerable functional proteasome inhibition are brought on in MM cells by co-suppressing β1 or β2 with β5activity[35], [36]. Interestingly, only high dose carfilzomib has been demonstrated to produce 2/5 co-inhibition and to be more lethal on MM cells among the existing PIs[37].

Section : Research Paper
ISSN 2063-5346



Fig 2 Proteasome inhibition in multiple myeloma [35]

Table1. Chemical and pharmacological features of different proteasome inhibitors [26-27][38]

Proteasome inhibitors	Active moiety	Binding kinetics	Therapeutic Targets	IC50 β5 (nM)	Half life (mins}	Route of administration
Bortezomib	Boronate	Reversible	β5>β1	5.7	110	IV or SC
Carfilzomib	Epoxyketone	Irreversible	β5>β2/β1	5	<30	IV
Ixazomib	Boronate	Reversible	β5>β1	5.9	18	Oral
Marizomib	β-lactone	Irreversible	β5>β2>β1	9.1	10-15	IV or SC
Oprozomib	Epoxyketone	Irreversible	β5	6-12	60-90	Oral
Dlanzomib	Boronate	Reversible	β5>β1	5.6	62 (hrs)	Oral

Section : Research Paper
ISSN 2063-5346

Bortezomib preclinical studies

It is now licenced for the treatment of myeloma in patients who have relapsed after transplant or as a second-line option for those who are not candidates[39], [40]. Bortezomib demonstrated several distinct anti-myeloma actions in preclinical tests, including altering the bone marrow microenvironment, inhibiting nuclear factor kappa B (NF-B), and disrupting cell cycle and inducing apoptosis[41], [42]. Major response rates of over 50% have been observed in the relapsed scenario, demonstrating the synergistic impact of bortezomib when used in conjunction with other chemotherapeutic drugs[43]. With response rates of 80% to 90% when bortezomib is administered in conjunction with other treatments, the first results from front-line therapy studies are encouraging[44]. More crucially, the capacity to mobilise peripheral blood stem cells is not compromised[45]–[49].

Table-2. Bortezomib with other therapeutic agents for first line therapy[50]–[56]

Drugs	Phase	No of patients	Median assemble cycle	Major no of rates (CP+PR)	Response rates	Toxicities
Bortezomib+/-, Dexamethasone	II	40	Upto 6 cycles given	85%	64%	Neuropathy, fatigue, constipation, neutropenia.
Bortezomib, Dexamethasone	II	18	16 patients received 4 cycles	83%	CR-17% VGPR-11% PR-55%	Neuropathy.
Bortezomib, Doxorubicin, Dexamethasone	I/II	21	19 patients received 4 cycles	95%	CR-24% VGPR-33% PR-33% n CR-5%	Neuropathy, postural hypotension.
Bortezomib, Melphalan, Prednisolone	I/II	53	3	84%	CR-28% n CR-11% PR-45% MR-2%	Myelosuppression, Neuropathy.
Bortezomib, Thalidomide, Dexamethasone	I/II	36	No more than 2 cycles needed for response	92%	CR-19% PR-73%	Neuropathy, DVT infection.

Section : Research Paper
ISSN 2063-5346

Table-3. Bortezomib with other therapeutic agents for relapsed and refractory disease[53], [57]–[68]

Study drugs	Phase	No of assessable patients	Median no of prior agents	Median no of cycles	Major response rate (CR+PR)	Toxicities
Bortezomib, Cyclophosphamide, Dexamethasone	II	50	2	6	76%	Neuropathy, thrombocytopenia, Cardiovascular events.
Bortezomib, Cyclophosphamide, Prednisolone	I/II	15	All had atleast 1 prior autograft.	2 patients completed.	31%	Infections, hypophosphatemia Cytopenia.
Bortezomib, Thalidomide +/-, Dexamethasone	I/II	85	66% received 2 prior autografts.	2-12 cycles given.	71%	Myelosuppression, neuropathy.
Bortezomib +/-, Methyl prednisolone, (weekly dosing)	II	28	70% prior autografts.	5	59%	Neuropathy, congestive heart failure.
Bortezomib, Dose melphalan +/- , dexamethasone	I/II	16	3	4	50% ORR (75% with dex)	Neuropathy, thrombocytopenia, Neutropenia.
Bortezomib, Melphalan	I/II	34	3	15 patients completed 8 cycles.	47%	Myelosuppression, neuropathy.
Bortezomib, melphalan, prednisolone, thalidomide	II	20	55% received 2 prior therapies.	3	50%	Thrombocytopenia, febrile neutropenia, neuropathy.
Bortezomib, Lenalidomide +/-, Dexamethasone	I	17	7	4	59%	Thrombocytopenia, hyponatraemia, hypotension.
Bortezomib, pegylated liposomal	I	22 patients with	5 all patients.	4	73%	Myelosuppression, fatigue, neuropathy,

doxorubicin		myeloma				diarrhoea.

Regimens including carfilzomib or ixazomib for relapsed and/or refractory MM
Carfilzomib binds permanently to the 5 subunit of the constitutive proteasome and suppresses chymotrypsin-like action[69], [70]. It was recently shown that carfilzomib cardiotoxicity is related to the autophagy process and increase of protein phosphatase to 2A phosphatase activity and not with proteasome function suppression[71], [72].

Table-4. Carfilzomib includes agents for relapsed and refractory disease[73]–[83]

Trials	Phase	Patients	Over all response (CR)	Median PFS (months)	Median OS (months)
ENDEAVOR (KD vs. VD)	III	929	77% vs. 63%	18.7 vs. 9.4	47.6 vs. 40.0
A.R.R.O.W. (weekly KD vs. twice weekly KD).	III	478	62.9% vs. 40.85% (7.1% vs. 1.7%)	11.2 vs. 7.6	(not reported)
ASPIRE (KRD vs. RD)	III	525	82% vs. 72% (16% vs. 8%).	26.3 vs. 17.6	48.3 vs. 40.4
DKD	Ib	85	84% (33%).	NR (74% and 66% at 12 and 18 months).	NR (82% at 12 months)
TOURMALINE MM1 (IRD vs. RD).	III	722	78% vs. 72% (12% vs. 7%).	20.6 vs.14.7	NR vs. NR

Nuclear factor kappa B pathway
Bortezomib's ability to block NF-kB, a restating factor connected to inflammation, by stabilising its inhibitor 1-B was the first justification for its use in treating cancer[84]. In addition to controlling different immunological and inflammatory responses, NF-B also plays a role in a number of tumour-related activities, including the inhibition of apoptosis and the stimulation of angiogenesis, proliferation, and migration[85]. As a result, NF-B suppression might stop the release of IL-6, which causes normal B cells to differentiate to their terminal state and encourages the formation of MM cells[86]. Because bortezomib activates the canonical pathway, which in turn inhibits inducible NF-B activity, bortezomib-induced

cytotoxicity cannot solely be attributed to the inhibition of canonical NF-B activity in MM because both the canonical and non-canonical pathways must be inhibited to effectively block total activity[87]–[89].

Deubiquitinating enzyme novel inhibitors

It is being looked into whether there are any new inhibitors that target the 20S proteasome's upstream DUBs or ubiquitin receptors. These substances could be able to overcome PI resistance. E3 ubiquitin ligases' adversaries are dubs. These ubiquitinated protein-recognizers, which also function as proteases, remove the ubiquitin tags from the proteins[90]. The anti-apoptotic protein Mcl-1 is stabilised in MM cells by the ubiquitin-specific processing protease 9x, which are widely conveyed in these cells[91]. In MM cells, the Usp9x inhibitor WP1130 induces apoptosis and decreases Mcl-1 expression[92]. Usp24, which was raised as a result of Usp9x decrease, has been shown to be essential for the survival of myeloma cells[93].Next, new 19S regulatory particle inhibitors are being researched. One of the 19S RP's lid subunits, Rpn11, gets rid of the polyubiquitin chains. Many cancer cells, includes bortezomib resistanting cells, have demonstrated the activity of CZM[94]. Now, research is also being done on the other two Rpn11 inhibitors, O phenanthroline and thiolutin[95], [96]. We anticipate the results of these inhibitors' additional clinical investigations.

Neuropathy induction

The most serious and frequent dose-limiting effect of PIs is peripheral neuropathy (PN). Current research on the pathophysiology and molecular basis of PN caused by bortezomib is inadequate. It has been discovered that bortezomib also inhibits the mitochondrial HtrA2/0ml ATP-dependent serine protease. Inhibition of HtrA2, which guards neurons against apoptosis, is now thought to be the root of PN in MM[97], [98]. Peptide epoxyketones, such as carfilzomib and oprozomib, exclusively block only Nterminal threonine active proteasome subunits, in contrast to bortezomib. Neutrophin dysregulation is a further suggested mechanism of bortezomib-induced PN generation because bortezomib inhibits NF-B activation and hinders the transcription of nerve growth factor-mediated neuron survival[99].

Future outlooks

As previously stated, triplet agents for MM containing of a PI, an IMiD, and dexamethasone has been studied. often it was used in the clinical setting. To increase the survival, individuals with MM who are eligible and ineligible for transplantation must achieve and sustain a deeper response. As previously stated, the data from Part 1 of the CASSIOPEIA research show that adding daratumumab to VTD has a therapeutic advantage in patients who are newly diagnosed MM and who are transplant candidates[100].

Conclusions

PIs are a crucial tool for improving PFS and increase the quality of life and are having a greater impact, particularly in patient subspecies with poor prognoses. In terms of therapy effectiveness, acceptable tolerability, administration, and quality of life for MM patients, further development of is now being conducted to assess the effectiveness and safety of new combination regimens incorporating PIs and other innovative medicines

.

Abbreviations

IV: intravenous, SC: subcutaneous, IC50: half maximal inhibitory concentration, CR-complete response; DVT- deep vein thrombosis; MR- minor response; n-CR – near complete response; ORR- over all response rate (CR+PR+MR); PR- partial response; VGPR-very good partial remission, CR-complete response; PR- partial response; MR- minor response; ORR-

Section : Research Paper
ISSN 2063-5346

overall response rate (CR+PR+MR), KD- carfilzomib + dexamethasone; VD- bortezomib + dexamethasone; RDlenalidomide + dexamethasone; KRD- carfilzomib + RD; DKD- daratumumab + KD; IRD- ixazomib + RD; ORR- overall response rate; CR- complete response; PFS- progression free survival; OS- overall survival; NR- not reached.

References

[1] W. Baumeister, J. Walz, F. Zühl, and E. Seemüller, "The Proteasome: Paradigm of a Self-Compartmentalizing Protease," *Cell*, vol. 92, no. 3, pp. 367–380, Feb. 1998, doi: 10.1016/S0092-8674(00)80929-0.

[2] O. Coux, K. Tanaka, and A. L. Goldberg, "STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES," *Annu Rev Biochem*, vol. 65, no. 1, pp. 801–847, Jun. 1996, doi: 10.1146/annurev.bi.65.070196.004101.

[3] G. N. DeMartino and T. G. Gillette, "Proteasomes: Machines for All Reasons," *Cell*, vol. 129, no. 4, pp. 659–662, May 2007, doi: 10.1016/j.cell.2007.05.007.

[4] G. R. Tundo *et al.*, "The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges," *Pharmacol Ther*, vol. 213, p. 107579, Sep. 2020, doi: 10.1016/j.pharmthera.2020.107579.

[5] K. TANAKA, "The proteasome: Overview of structure and functions," *Proceedings of the Japan Academy, Series B*, vol. 85, no. 1, pp. 12–36, 2009, doi: 10.2183/pjab.85.12.

[6] J. A. Maupin- Furlow *et al.*, "Proteasomes from Structure to Function: Perspectives from Archaea," 2006, pp. 125–169. doi: 10.1016/S0070-2153(06)75005-0.

[7] T. Yoshimura *et al.*, "Molecular Characterization of the '26S' Proteasome Complex from Rat Liver," *J Struct Biol*, vol. 111, no. 3, pp. 200–211, Nov. 1993, doi: 10.1006/jsbi.1993.1050.

[8] T. Jung and T. Grune, "The proteasome and its role in the degradation of oxidized proteins," *IUBMB Life*, vol. 60, no. 11, pp. 743–752, Nov. 2008, doi: 10.1002/iub.114.

[9] C.-W. Liu, M. J. Corboy, G. N. DeMartino, and P. J. Thomas, "Endoproteolytic Activity of the Proteasome," *Science (1979)*, vol. 299, no. 5605, pp. 408–411, Jan. 2003, doi: 10.1126/science.1079293.

[10] H. Fu, J. H. Doelling, C. S. Arendt, M. Hochstrasser, and R. D. Vierstra, "Molecular Organization of the 20S Proteasome Gene Family from Arabidopsis thaliana," *Genetics*, vol. 149, no. 2, pp. 677–692, Jun. 1998, doi: 10.1093/genetics/149.2.677.

[11] M. H. Glickman, D. M. Rubin, V. A. Fried, and D. Finley, "The Regulatory Particle of the *Saccharomyces cerevisiae* Proteasome," *Mol Cell Biol*, vol. 18, no. 6, pp. 3149–3162, Jun. 1998, doi: 10.1128/MCB.18.6.3149.

[12] Shaik Firoz, Ramu Samineni, Y Ratna Sindhu, C Radhika, MS Srikanth, Penumala Prudhvi. Monkeypox: A comprehensive review on transmission, clinical features and management of human monkeypox. *European Journal of Molecular & Clinical Medicine.* 2022; 9(8): 103-119.

Section : Research Paper
ISSN 2063-5346

[13] Ramu Samineni, Jithendra Chimakurthy, Sathish Kumar Konidala, Udayaratna K, Devatulasi K, Ager Dengoc. Effect of Hydroxy propyl methyl cellulose and microcrystalline cellulose in design and optimization of Nebivolol Hydrochloride immediate release tablets by response surface methodology. *International Journal of Research in Pharmaceutical Science.* 2021; 12(3): 1990-1998.

[14] Saravanakumar K, Ashok Thulluru, Ramu Samineni, Effect of Sodium Alginate in Combination with Natural and Synthetic Polymers on the Release of Verapamil HCL from its Floating Microspheres, *J. Pharm. Sci. & Res.* 2019, 11(5): 2028-2035.

[15] C. Wójcik, K. Tanaka, N. Paweletz, U. Naab, and S. Wilk, "Proteasome activator (PA28) subunits, α, β and γ (Ki antigen) in NT2 neuronal precursor cells and HeLa S3 cells," *Eur J Cell Biol*, vol. 77, no. 2, pp. 151–160, Oct. 1998, doi: 10.1016/S0171-9335(98)80083-6.

[16] F. G. Whitby *et al.*, "Structural basis for the activation of 20S proteasomes by 11S regulators," *Nature*, vol. 408, no. 6808, pp. 115–120, Nov. 2000, doi: 10.1038/35040607.

[17] M. Schmidt *et al.*, "The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle," *Nat Struct Mol Biol*, vol. 12, no. 4, pp. 294–303, Apr. 2005, doi: 10.1038/nsmb914.

[18] V. Ustrell, "PA200, a nuclear proteasome activator involved in DNA repair," *EMBO J*, vol. 21, no. 13, pp. 3516–3525, Jul. 2002, doi: 10.1093/emboj/cdf333.

[19] M. Fehlker, P. Wendler, A. Lehmann, and C. Enenkel, "Blm3 is part of nascent proteasomes and is involved in a late stage of nuclear proteasome assembly," *EMBO Rep*, vol. 4, no. 10, pp. 959–963, Oct. 2003, doi: 10.1038/sj.embor.embor938.

[20] A. J. Marques, C. Glanemann, P. C. Ramos, and R. J. Dohmen, "The C-terminal Extension of the β7 Subunit and Activator Complexes Stabilize Nascent 20 S Proteasomes and Promote Their Maturation," *Journal of Biological Chemistry*, vol. 282, no. 48, pp. 34869–34876, Nov. 2007, doi: 10.1074/jbc.M705836200.

[21] S. L. McCutchen-Maloney *et al.*, "cDNA Cloning, Expression, and Functional Characterization of PI31, a Proline-rich Inhibitor of the Proteasome," *Journal of Biological Chemistry*, vol. 275, no. 24, pp. 18557–18565, Jun. 2000, doi: 10.1074/jbc.M001697200.

[22] Ramu Samineni, Jithendra Chimakurthy, K Sumalatha, G Dharani, J Rachana, K Manasa, P Anitha. Co-crystals: a review of recent trends in co crystallization of BCS class II drugs. Research Journal of Pharmacy and Technology. 2019; 12(7): 3117-3124.

[23] Ramu Samineni, Jithendra Chimakurthy. Effect of Coformers on Novel Co-Crystals of Gabapentin: An In Vivo Approach. Journal of Pharmaceutical Sciences and Research. 2018; 12(5): 639-648

[24] Ramu Samineni *, M Anil Kumar, J Malisha, K Pavani, K Bhavyasree, E R Nithin. Formulation and Evaluation of Topical Solid Lipid Nanoparticulate System of Aceclofenac. Int J Pharma Res Health Sci. 2018; 6(4): 2647-2650.

[25] R. Verma *et al.*, "Proteasomal Proteomics: Identification of Nucleotide-sensitive Proteasome-interacting Proteins by Mass Spectrometric Analysis of Affinity-purified Proteasomes," *Mol Biol Cell*, vol. 11, no. 10, pp. 3425–3439, Oct. 2000, doi: 10.1091/mbc.11.10.3425.

[26] X. Wang, C.-F. Chen, P. R. Baker, P. Chen, P. Kaiser, and L. Huang, "Mass Spectrometric Characterization of the Affinity-Purified Human 26S Proteasome Complex," *Biochemistry*, vol. 46, no. 11, pp. 3553–3565, Mar. 2007, doi: 10.1021/bi061994u.

[27] S. Ito, "Proteasome Inhibitors for the Treatment of Multiple Myeloma," *Cancers (Basel)*, vol. 12, no. 2, p. 265, Jan. 2020, doi: 10.3390/cancers12020265.

[28] N. Mitsiades *et al.*, "Molecular sequelae of proteasome inhibition in human multiple myeloma cells," *Proceedings of the National Academy of Sciences*, vol. 99, no. 22, pp. 14374–14379, Oct. 2002, doi: 10.1073/pnas.202445099.

[29] S. K. Kumar *et al.*, "Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients," *Leukemia*, vol. 28, no. 5, pp. 1122–1128, May 2014, doi: 10.1038/leu.2013.313.

[30] A. Allegra, A. Alonci, D. Gerace, V. Innao, L. Calabrò, and C. Musolino, "New orally active proteasome inhibitors in multiple myeloma," *Leuk Res*, vol. 38, no. 1, pp. 1–9, Jan. 2014, doi: 10.1016/j.leukres.2013.10.018.

[31] K. Okazuka and T. Ishida, "Proteasome inhibitors for multiple myeloma," *Jpn J Clin Oncol*, vol. 48, no. 9, pp. 785–793, Sep. 2018, doi: 10.1093/jjco/hyy108.

[32] L. Kubiczkova, L. Pour, L. Sedlarikova, R. Hajek, and S. Sevcikova, "Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma," *J Cell Mol Med*, vol. 18, no. 6, pp. 947–961, Jun. 2014, doi: 10.1111/jcmm.12279.

[33] J. Adams, "The proteasome: a suitable antineoplastic target," *Nat Rev Cancer*, vol. 4, no. 5, pp. 349–360, May 2004, doi: 10.1038/nrc1361.

[34] D. Niewerth, G. Jansen, Y. G. Assaraf, S. Zweegman, G. J. L. Kaspers, and J. Cloos, "Molecular basis of resistance to proteasome inhibitors in hematological malignancies," *Drug Resistance Updates*, vol. 18, pp. 18–35, Jan. 2015, doi: 10.1016/j.drup.2014.12.001.

[35] A. Besse *et al.*, "Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors," *Cell Chem Biol*, vol. 26, no. 3, pp. 340-351.e3, Mar. 2019, doi: 10.1016/j.chembiol.2018.11.007.

[36] R. Yadav, U. K. Nath, I. Celik, S. Handu, N. Jain, and P. Dhamija, "Identification and in-vitro analysis of potential proteasome inhibitors targeting PSMβ5 for multiple myeloma," *Biomedicine & Pharmacotherapy*, vol. 157, p. 113963, Jan. 2023, doi: 10.1016/j.biopha.2022.113963.

[37] V. T. de M. Hungria *et al.*, "New proteasome inhibitors in the treatment of multiple myeloma," *Hematol Transfus Cell Ther*, vol. 41, no. 1, pp. 76–83, Jan. 2019, doi: 10.1016/j.htct.2018.07.003.

[38] J. Brayer and R. Baz, "The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma," *Ther Adv Hematol*, vol. 8, no. 7, pp. 209–220, Jul. 2017, doi: 10.1177/2040620717710171.

[39] D. Chen, M. Frezza, S. Schmitt, J. Kanwar, and Q. P. Dou, "Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives," *Curr Cancer Drug Targets*, vol. 11, no. 3, pp. 239–253, Mar. 2011, doi: 10.2174/156800911794519752.

[40] M. Boccadoro, G. Morgan, and J. Cavenagh, "Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy," *Cancer Cell Int*, vol. 5, no. 1, p. 18, Dec. 2005, doi: 10.1186/1475-2867-5-18.

[41] A. Field-Smith, G. J. Morgan, and F. E. Davies, "Bortezomib (Velcade?) in the treatment of multiple myeloma," *Ther Clin Risk Manag*, vol. 2, no. 3, pp. 271–279, Jan. 2006, doi: 10.2147/tcrm.2006.2.3.271.

[42] H. Gu, X. Chen, G. Gao, and H. Dong, "Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells," *Mol Cancer Ther*, vol. 7, no. 8, pp. 2298–2307, Aug. 2008, doi: 10.1158/1535-7163.MCT-08-0186.

[43] N. Reddy and M. S. Czuczman, "Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies," *Annals of Oncology*, vol. 21, no. 9, pp. 1756–1764, Sep. 2010, doi: 10.1093/annonc/mdq009.

[44] J. F. San Miguel *et al.*, "Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma," *New England Journal of Medicine*, vol. 359, no. 9, pp. 906–917, Aug. 2008, doi: 10.1056/NEJMoa0801479.

[45] A. Corso *et al.*, "Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma," *Leuk Lymphoma*, vol. 51, no. 2, pp. 236–242, Feb. 2010, doi: 10.3109/10428190903452826.

[46] J.-L. Harousseau *et al.*, "Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial," *Journal of Clinical Oncology*, vol. 28, no. 30, pp. 4621–4629, Oct. 2010, doi: 10.1200/JCO.2009.27.9158.

[47] J.-L. Harousseau *et al.*, "Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.," *Haematologica*, vol. 91, no. 11, pp. 1498–505, Nov. 2006.

[48] M. Cavo *et al.*, "Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study," *The Lancet*, vol. 376, no. 9758, pp. 2075–2085, Dec. 2010, doi: 10.1016/S0140-6736(10)61424-9.

[49] K. Hatano *et al.*, "Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma," *Oncogene*, vol. 28, no. 2, pp. 231–242, Jan. 2009, doi: 10.1038/onc.2008.385.

[50] E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington, K. P. Lee, and L. H. Boise, "Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells," *Blood*, vol. 107, no. 12, pp. 4907–4916, Jun. 2006, doi: 10.1182/blood-2005-08-3531.

[51] S. Jagannath *et al.*, "Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma," *Br J Haematol*, vol. 129, no. 6, pp. 776–783, Jun. 2005, doi: 10.1111/j.1365-2141.2005.05540.x.

[52] M.-V. Mateos *et al.*, "Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study," *Blood*, vol. 108, no. 7, pp. 2165–2172, Oct. 2006, doi: 10.1182/blood-2006-04-019778.

[53] R. Popat *et al.*, "A Phase I/II Study of Bortezomib and Low Dose Intravenous Melphalan (BM) for Relapsed Multiple Myeloma.," *Blood*, vol. 106, no. 11, pp. 2555–2555, Nov. 2005, doi: 10.1182/blood.V106.11.2555.2555.

[54] L. M. Wang, D. M. Weber, K. B. Delasalle, and R. Alexanian, "VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.," *Blood*, vol. 104, no. 11, pp. 210–210, Nov. 2004, doi: 10.1182/blood.V104.11.210.210.

[55] W. I. Bensinger *et al.*, "Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma," *Br J Haematol*, vol. 148, no. 4, pp. 562–568, Feb. 2010, doi: 10.1111/j.1365-2141.2009.07981.x.

[56] S. Jagannath *et al.*, "Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma," *Br J Haematol*, vol. 146, no. 6, pp. 619–626, Sep. 2009, doi: 10.1111/j.1365-2141.2009.07803.x.

[57] M. Kropff *et al.*, "Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma," *Br J Haematol*, vol. 138, no. 3, pp. 330–337, Aug. 2007, doi: 10.1111/j.1365-2141.2007.06656.x.

[58] R. Z. Orlowski *et al.*, "Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic

malignancies," *Blood*, vol. 105, no. 8, pp. 3058–3065, Apr. 2005, doi: 10.1182/blood-2004-07-2911.

[59] A. Palumbo *et al.*, "Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.," *Blood*, vol. 106, no. 11, pp. 2553–2553, Nov. 2005, doi: 10.1182/blood.V106.11.2553.2553.

[60] D. E. Reece, G. Piza, S. Trudel, C. Chen, J. R. Mikhael, and A. K. Stewart, "A Phase I–II Trial of Bortezomib (Velcade) (Vc) and Oral Cyclophosphamide (CY) Plus Prednisone (P) for Relapsed/Refractory Multiple Myeloma (MM).," *Blood*, vol. 106, no. 11, pp. 2556–2556, Nov. 2005, doi: 10.1182/blood.V106.11.2556.2556.

[61] A. Suvannasankha, G. G. Smith, and R. Abonour, "Weekly Bortezomib with or without Glucocorticosteroids Is Effective in Patients with Relapsed or Refractory Multiple Myeloma.," *Blood*, vol. 106, no. 11, pp. 2562–2562, Nov. 2005, doi: 10.1182/blood.V106.11.2562.2562.

[62] M. Zangari *et al.*, "Velcade (V)-Thalidomide (T)-Dexamethasone (D) for Advanced and Refractory Multiple Myeloma (MM): Long-Term Follow-Up of Phase I–II Trial UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T.," *Blood*, vol. 106, no. 11, pp. 2552–2552, Nov. 2005, doi: 10.1182/blood.V106.11.2552.2552.

[63] J.-S. Ahn *et al.*, "A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma," *Ann Hematol*, vol. 91, no. 7, pp. 1023–1030, Jul. 2012, doi: 10.1007/s00277-012-1420-7.

[64] T. Facon, "Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy," *Blood*, vol. 107, no. 4, pp. 1292–1298, Feb. 2006, doi: 10.1182/blood-2005-04-1588.

[65] W. Fu *et al.*, "Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma," *Am J Clin Oncol*, vol. 35, no. 6, pp. 562–565, Dec. 2012, doi: 10.1097/COC.0b013e31822043f6.

[66] P. G. Richardson *et al.*, "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma," *Blood*, vol. 116, no. 5, pp. 679–686, Aug. 2010, doi: 10.1182/blood-2010-02-268862.

[67] P. G. Richardson *et al.*, "Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma," *New England Journal of Medicine*, vol. 352, no. 24, pp. 2487–2498, Jun. 2005, doi: 10.1056/NEJMoa043445.

[68] P. G. Richardson *et al.*, "A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma," *New England Journal of Medicine*, vol. 348, no. 26, pp. 2609–2617, Jun. 2003, doi: 10.1056/NEJMoa030288.

[69] M. Wang *et al.*, "Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple

myeloma," *Blood*, vol. 122, no. 18, pp. 3122–3128, Oct. 2013, doi: 10.1182/blood-2013-07-511170.

[70] K. Tzogani *et al.*, "European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy," *ESMO Open*, vol. 4, no. 5, p. e000570, 2019, doi: 10.1136/esmoopen-2019-000570.

[71] N. Gupta *et al.*, "Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses," *Target Oncol*, vol. 12, no. 5, pp. 643–654, Oct. 2017, doi: 10.1007/s11523-017-0524-3.

[72] T. M. Herndon *et al.*, "U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma," *Clinical Cancer Research*, vol. 19, no. 17, pp. 4559–4563, Sep. 2013, doi: 10.1158/1078-0432.CCR-13-0755.

[73] A. Chari *et al.*, "Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma," *Blood*, vol. 134, no. 5, pp. 421–431, Aug. 2019, doi: 10.1182/blood.2019000722.

[74] M. A. Dimopoulos *et al.*, "Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study," *Lancet Oncol*, vol. 17, no. 1, pp. 27–38, Jan. 2016, doi: 10.1016/S1470-2045(15)00464-7.

[75] P. Moreau *et al.*, "Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma," *New England Journal of Medicine*, vol. 374, no. 17, pp. 1621–1634, Apr. 2016, doi: 10.1056/NEJMoa1516282.

[76] P. Moreau *et al.*, "Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study," *Lancet Oncol*, vol. 19, no. 7, pp. 953–964, Jul. 2018, doi: 10.1016/S1470-2045(18)30354-1.

[77] A. K. Stewart *et al.*, "Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma," *New England Journal of Medicine*, vol. 372, no. 2, pp. 142–152, Jan. 2015, doi: 10.1056/NEJMoa1411321.

[78] J. R. Berenson *et al.*, "CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma," *Blood*, vol. 127, no. 26, pp. 3360–3368, Jun. 2016, doi: 10.1182/blood-2015-11-683854.

[79] K. Groen, N. W. C. J. van de Donk, C. Stege, S. Zweegman, and I. S. Nijhof, " Carfilzomib for relapsed and refractory multiple myeloma ," *Cancer Manag Res*, vol. Volume 11, pp. 2663–2675, Apr. 2019, doi: 10.2147/CMAR.S150653.

[80] K. P. Papadopoulos *et al.*, "Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma," *Journal of Clinical Oncology*, vol. 33, no. 7, pp. 732–739, Mar. 2015, doi: 10.1200/JCO.2013.52.3522.

[81] M. A. Dimopoulos *et al.*, "Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial," *The Lancet*, vol. 393, no. 10168, pp. 253–264, Jan. 2019, doi: 10.1016/S0140-6736(18)33003-4.

[82] N. Lendvai *et al.*, "A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma," *Blood*, vol. 124, no. 6, pp. 899–906, Aug. 2014, doi: 10.1182/blood-2014-02-556308.

[83] R. Niesvizky *et al.*, "Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma," *Clinical Cancer Research*, vol. 19, no. 8, pp. 2248–2256, Apr. 2013, doi: 10.1158/1078-0432.CCR-12-3352.

[84] E. B. Traenckner, S. Wilk, and P. A. Baeuerle, "A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.," *EMBO J*, vol. 13, no. 22, pp. 5433–5441, Nov. 1994, doi: 10.1002/j.1460-2075.1994.tb06878.x.

[85] Z.-W. Li, H. Chen, R. A. Campbell, B. Bonavida, and J. R. Berenson, "NF-??B in the pathogenesis and treatment of multiple myeloma," *Curr Opin Hematol*, vol. 15, no. 4, pp. 391–399, Jul. 2008, doi: 10.1097/MOH.0b013e328302c7f4.

[86] B. A. Barut *et al.*, "Role of interleukin 6 in the growth of myelomaderived cell lines," *Leuk Res*, vol. 16, no. 10, pp. 951–959, Oct. 1992, doi: 10.1016/0145-2126(92)90073-G.

[87] C. Fabre *et al.*, "Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma," *Clinical Cancer Research*, vol. 18, no. 17, pp. 4669–4681, Sep. 2012, doi: 10.1158/1078-0432.CCR-12-0779.

[88] T. Hideshima *et al.*, "Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells," *Blood*, vol. 114, no. 5, pp. 1046–1052, Jul. 2009, doi: 10.1182/blood-2009-01-199604.

[89] J. J. Keats *et al.*, "Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma," *Cancer Cell*, vol. 12, no. 2, pp. 131–144, Aug. 2007, doi: 10.1016/j.ccr.2007.07.003.

[90] J. Adams *et al.*, "Proteasome inhibitors: a novel class of potent and effective antitumor agents.," *Cancer Res*, vol. 59, no. 11, pp. 2615–22, Jun. 1999.

[91] M. Schwickart *et al.*, "Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival," *Nature*, vol. 463, no. 7277, pp. 103–107, Jan. 2010, doi: 10.1038/nature08646.

[92] M. Hu *et al.*, "Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14," *EMBO J*, vol. 24, no. 21, pp. 3747–3756, Nov. 2005, doi: 10.1038/sj.emboj.7600832.

[93] D. Chauhan *et al.*, "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance," *Cancer Cell*, vol. 22, no. 3, pp. 345–358, Sep. 2012, doi: 10.1016/j.ccr.2012.08.007.

[94] K. H. Ventii and K. D. Wilkinson, "Protein partners of deubiquitinating enzymes," *Biochemical Journal*, vol. 414, no. 2, pp. 161–175, Sep. 2008, doi: 10.1042/BJ20080798.

[95] L. Lauinger *et al.*, "Thiolutin is a zinc chelator that inhibits the Rpn11 and other JAMM metalloproteases," *Nat Chem Biol*, vol. 13, no. 7, pp. 709–714, Jul. 2017, doi: 10.1038/nchembio.2370.

[96] Y. Song *et al.*, "Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance," *Oncogene*, vol. 36, no. 40, pp. 5631–5638, Oct. 2017, doi: 10.1038/onc.2017.172.

[97] S. Arastu-Kapur *et al.*, "Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events," *Clinical Cancer Research*, vol. 17, no. 9, pp. 2734–2743, May 2011, doi: 10.1158/1078-0432.CCR-10-1950.

[98] P. Gomez-Bougie *et al.*, "Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma," *Cancer Res*, vol. 67, no. 11, pp. 5418–5424, Jun. 2007, doi: 10.1158/0008-5472.CAN-06-4322.

[99] P. G. Richardson, T. Hideshima, and K. C. Anderson, "Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers," *Cancer Control*, vol. 10, no. 5, pp. 361–369, Sep. 2003, doi: 10.1177/107327480301000502.

[100] P. Moreau *et al.*, "Proteasome inhibitors in multiple myeloma: 10 years later," *Blood*, vol. 120, no. 5, pp. 947–959, Aug. 2012, doi: 10.1182/blood-2012-04-403733.